Get started

Financials · ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) financials

For the twelve months ended Sep 30, 2026, Arcturus Therapeutics Holdings Inc. reported $30.51M of revenue and -$87.24M of net income.

Revenue, TTM
$30.51M
Revenue growth, YoY
-68.7%
Net income, TTM
-$87.24M
Net margin
-285.9%
Free cash flow, TTM
-$62.62M
EPS, diluted, TTM
-$3.10
Cash
$184.82M
P/S
8.96
Market cap
$273.5M
Annual revenue$82.03M
FY2018FY2025
Annual net income-$65.78M
FY2018FY2025
Annual free cash flow-$74.50M
FY2018FY2025

ARCT revenue and earnings growth

ARCT revenueQ3 2026$18.30M

Quarter YoY
+6.7%
QoQ
+518.4%
FY YoY
-46.1%
5Y CAGR
+53.8%

ARCT revenue was $18.30M in fiscal Q3 2026 (ended Sep 30, 2026), up 6.7% from a year earlier and up 518.4% from the prior quarter. For the full fiscal 2025 it was $82.03M, down 46.1% from fiscal 2024. Compound annual growth was +53.8% over 5 years. It rose in 3 of the last 7 fiscal years.

ARCT net incomeQ3 2026-$7.41M

ARCT net income was -$7.41M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$13.45M a year earlier. For the full fiscal 2025 it was -$65.78M, compared with -$80.94M in fiscal 2024.

ARCT EPSQ3 2026-$0.26

ARCT diluted EPS was -$0.26 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.49 a year earlier. For the full fiscal 2025 it was -$2.40, compared with -$3.00 in fiscal 2024.

ARCT free cash flowQ3 2026-$6.96M

ARCT free cash flow was -$6.96M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$17.33M a year earlier. For the full fiscal 2025 it was -$74.50M, compared with -$60.40M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$82.03M$152.31M$166.80M$206.00M$12.36M$9.54M$20.79M$15.75M
Research and development$112.21M$195.16M$192.13M$147.75M$173.76M$57.85M$33.64M$16.98M
Selling, general and admin$46.08M$52.82M$52.87M$46.07M$41.45M$23.22M$12.66M$20.58M
Operating income-$76.26M-$95.67M-$78.20M$12.18M-$202.85M-$71.52M-$25.51M-$21.81M
Pre-tax income-$65.78M-$80.94M-$27.89M$10.64M-$203.67M-$72.15M-$25.99M-$21.79M
Income tax--$4.0K$1.83M$1.29M----
Net income-$65.78M-$80.94M-$29.73M$9.35M-$203.67M-$72.15M-$25.99M-$21.79M
EPS, basic-$2.40-$3.00-$1.12$0.35-$7.74-$3.55-$2.15-$2.16
EPS, diluted-$2.40-$3.00-$1.12$0.35-$7.74-$3.55-$2.15-$2.16
Diluted shares27.4M27.0M26.6M27.1M26.3M20.3M12.1M10.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$230.91M$293.91M$292.00M$393.98M$372.57M$463.00M$71.35M$36.82M
Receivables$5.56M$3.97M$32.06M$2.76M$3.37M$2.13M$2.18M$4.48M
Current assets$241.45M$305.98M$386.59M$403.33M$378.96M$467.79M$74.29M$41.83M
Total assets$271.15M$344.07M$429.40M$450.39M$392.81M$476.46M$82.14M$44.20M
Current liabilities$36.38M$65.49M$81.99M$126.98M$99.54M$49.52M$21.32M$12.58M
Short-term debt---$60.66M$22.47M$1.25M--
Long-term debt----$40.63M$13.85M$14.99M$9.91M
Total debt----$63.11M$15.10M$14.99M$9.91M
Total liabilities$57.16M$103.09M$150.89M$180.07M$164.60M$79.90M$56.35M$30.56M
Shareholders' equity$213.99M$240.98M$278.51M$270.31M$228.21M$396.55M$25.79M$13.64M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow-$74.27M-$59.75M-$18.10M$31.99M-$135.04M-$42.86M-$6.45M-$20.76M
Capital expenditures$230.0K$648.0K$2.90M$7.73M$3.41M$1.74M$818.0K$1.48M
Free cash flow-$74.50M-$60.40M-$21.00M$24.27M-$138.45M-$44.60M-$7.26M-$22.24M
Investing cash flow-$230.0K-$648.0K-$2.90M-$7.73M-$3.41M-$1.74M-$818.0K$22.13M
Financing cash flow$13.38M$5.42M-$24.09M-$2.86M$48.02M$436.14M$41.91M$10.20M
Stock-based compensation$25.41M$37.99M$34.65M$30.61M$28.91M$6.76M$1.98M$1.26M
Depreciation and amortization$3.02M$3.54M$2.96M$1.53M$1.19M$882.0K$684.0K$582.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY-46.1%-8.7%-19.0%1566.8%29.6%-54.1%32.0%-
Operating margin-93.0%-62.8%-46.9%5.9%-1641.3%-749.8%-122.7%-138.5%
Net margin-80.2%-53.1%-17.8%4.5%-1648.0%-756.3%-125.0%-138.3%
Free cash flow margin-90.8%-39.7%-12.6%11.8%-1120.2%-467.6%-34.9%-141.2%
Return on equity-30.7%-33.6%-10.7%3.5%-89.2%-18.2%-100.8%-159.7%
Return on assets-24.3%-23.5%-6.9%2.1%-51.8%-15.1%-31.6%-49.3%
Current ratio6.644.674.723.183.819.453.483.33
Debt to equity----0.280.040.580.73

Source: XBRL data Arcturus Therapeutics Holdings Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ARCT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ARCT$30.51M-68.7%-$87.24M-285.9%$273.5M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

ARCT FAQ

8 questions
  • What is ARCT revenue?
    Arcturus Therapeutics Holdings Inc. (ARCT) reported $30.51M of revenue for the twelve months ended Sep 30, 2026. That is down 68.7% from the year before. Revenue for fiscal 2025 was $82.03M.
  • Is ARCT profitable?
    No. Arcturus Therapeutics Holdings Inc. reported a net loss of $87.24M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ARCT have?
    Arcturus Therapeutics Holdings Inc. reported $184.82M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ARCT revenue growing?
    Arcturus Therapeutics Holdings Inc.'s revenue changed -46.1% in fiscal 2025, to $82.03M. Its compound annual growth rate was +53.8% over 5 years.
  • What is ARCT free cash flow?
    Arcturus Therapeutics Holdings Inc. generated -$62.62M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$62.48M less capital expenditures.
  • What is ARCT earnings per share?
    Diluted earnings per share were -$3.10 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ARCT last report financial results?
    The latest statements here come from Arcturus Therapeutics Holdings Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this ARCT financial data come from?
    Quantisnow builds these statements from the structured XBRL data Arcturus Therapeutics Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.